Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease

被引:6
|
作者
Li, Zhen [1 ]
Ouyang, Hao [1 ]
Zhu, Junfeng [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Liver, Shanghai, Peoples R China
关键词
metabolic-related fatty liver disease; immune cells; traditional Chinese medicine prescription; natural product; herb component; treatment; INDUCED NONALCOHOLIC STEATOHEPATITIS; ENDOPLASMIC-RETICULUM STRESS; RHUS-VERNICIFERA STOKES; MACROPHAGE POLARIZATION; INSULIN-RESISTANCE; LIPID-METABOLISM; ADIPOSE-TISSUE; KAPPA-B; INFLAMMATION; MICE;
D O I
10.3389/fphar.2023.1195146
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
MAFLD stands for metabolic-related fatty liver disease, which is a prevalent liver disease affecting one-third of adults worldwide, and is strongly associated with obesity, hyperlipidemia, and type 2 diabetes. It encompasses a broad spectrum of conditions ranging from simple liver fat accumulation to advanced stages like chronic inflammation, tissue damage, fibrosis, cirrhosis, and even hepatocellular carcinoma. With limited approved drugs for MAFLD, identifying promising drug targets and developing effective treatment strategies is essential. The liver plays a critical role in regulating human immunity, and enriching innate and adaptive immune cells in the liver can significantly improve the pathological state of MAFLD. In the modern era of drug discovery, there is increasing evidence that traditional Chinese medicine prescriptions, natural products and herb components can effectively treat MAFLD. Our study aims to review the current evidence supporting the potential benefits of such treatments, specifically targeting immune cells that are responsible for the pathogenesis of MAFLD. By providing new insights into the development of traditional drugs for the treatment of MAFLD, our findings may pave the way for more effective and targeted therapeutic approaches.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine
    Shao, Mingmei
    Lu, Yifei
    Xiang, Hongjiao
    Wang, Junmin
    Ji, Guang
    Wu, Tao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?
    Chan, Yau-Tuen
    Wang, Ning
    Tan, Hor Yue
    Li, Sha
    Feng, Yibin
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [23] Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment
    Guo, Xiangyu
    Yin, Xunzhe
    Liu, Zuojia
    Wang, Jin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [24] Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials
    Zuanji Liang
    Xianwen Chen
    Junnan Shi
    Hao Hu
    Yan Xue
    Carolina Oi Lam Ung
    Chinese Medicine, 16
  • [25] Effectiveness and safety of traditional Chinese medicines for non-alcoholic fatty liver disease Protocol for systematic review and meta-analysis
    Qin, Manman
    Yuan, Fuqiang
    Ren, Jiankun
    Chi, Zhenhai
    MEDICINE, 2020, 99 (25) : E20699
  • [26] Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials
    Liang, Zuanji
    Chen, Xianwen
    Shi, Junnan
    Hu, Hao
    Xue, Yan
    Ung, Carolina Oi Lam
    CHINESE MEDICINE, 2021, 16 (01)
  • [27] Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer
    Cheng, Can
    Zhuo, Songming
    Zhang, Bo
    Zhao, Xu
    Liu, Ying
    Liao, Chaoliang
    Quan, Jing
    Li, Zhenzhen
    Bode, Ann M.
    Cao, Ya
    Luo, Xiangjian
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (08): : 1654 - 1663
  • [28] Immune cells in metabolic associated fatty liver disease: Global trends and hotspots (2004-2024)
    Qi, Wen-Ying
    Zheng, Shi-Hao
    Li, Si-Ze
    Wang, Wei
    Wang, Qiu-Yue
    Liu, Qi-Yao
    Li, Xiao-Ke
    Zhang, Jia-Xin
    Gan, Da-Nan
    Ye, Yong-An
    Zao, Xiao-Bin
    WORLD JOURNAL OF HEPATOLOGY, 2025, 17 (03)
  • [29] Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
    Alisi, Anna
    Mccaughan, Geoffrey
    Gronbaek, Henning
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 861 - 872
  • [30] Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease
    Zhou, Honglin
    Ma, Cheng
    Wang, Cheng
    Gong, Lihong
    Zhang, Yafang
    Li, Yunxia
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 898